zp54bv

Property	Value
?:abstract	BACKGROUND: Hydroxychloroquine has not been associated with improved survival among hospitalized COVID-19 patients in the majority of observational studies and similarly was not identified as an effective prophylaxis following exposure in a prospective randomized trial. We aimed to explore the role of hydroxychloroquine therapy in mildly symptomatic patients diagnosed in the outpatient setting. METHODS: We examined the association between outpatient hydroxychloroquine exposure and the subsequent progression of disease among mildly symptomatic non-hospitalized patients with documented SARS-CoV-2 infection. The primary outcome assessed was requirement of hospitalization. Data was obtained from a retrospective review of electronic health records within a New Jersey USA multi-hospital network. We compared outcomes in patients who received hydroxychloroquine with those who did not applying a multivariable logistic model with propensity matching. RESULTS: Among 1274 outpatients with documented SARS-CoV-2 infection 7.6% were prescribed hydroxychloroquine. In a 1067 patient propensity matched cohort, 21.6% with outpatient exposure to hydroxychloroquine were hospitalized, and 31.4% without exposure were hospitalized. In the primary multivariable logistic regression analysis with propensity matching there was an association between exposure to hydroxychloroquine and a decreased rate of hospitalization from COVID-19 (OR 0.53; 95% CI, 0.29, 0.95). Sensitivity analyses revealed similar associations. QTc prolongation events occurred in 2% of patients prescribed hydroxychloroquine with no reported arrhythmia events among those with data available. CONCLUSIONS: In this retrospective observational study of SARS-CoV-2 infected non-hospitalized patients hydroxychloroquine exposure was associated with a decreased rate of subsequent hospitalization. Additional exploration of hydroxychloroquine in this mildly symptomatic outpatient population is warranted. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-021-05773-w.
?:creator	<https://research.tib.eu/covid-19/entity/Ip%2C_Andrew%3B_Ahn%2C_Jaeil%3B_Zhou%2C_Yizhao%3B_Goy%2C_Andre_H.%3B_Hansen%2C_Eric%3B_Pecora%2C_Andrew_L.%3B_Sinclaire%2C_Brittany_A.%3B_Bednarz%2C_Urszula%3B_Marafelias%2C_Michael%3B_Sawczuk%2C_Ihor_S.%3B_Underwood%2C_Joseph_P.%3B_Walker%2C_David_M.%3B_Prasad%2C_Rajiv%3B_Sweeney%2C_Robert_L.%3B_Ponce%2C_Marie_G.%3B_La_Capra%2C_Samuel%3B_Cunningham%2C_Frank_J.%3B_Calise%2C_Arthur_G.%3B_Pulver%2C_Bradley_L.%3B_Ruocco%2C_Dominic%3B_Mojares%2C_Greggory_E.%3B_Eagan%2C_Michael_P.%3B_Ziontz%2C_Kristy_L.%3B_Mastrokyriakos%2C_Paul%3B_Goldberg%2C_Stuart_L.>
?:doi	10.1186/s12879-021-05773-w
?:doi	<https://research.tib.eu/covid-19/entity/10.1186/s12879-021-05773-w>
?:journal	BMC_Infect_Dis
?:license	cc-by
?:pdf_json_files	document_parses/pdf_json/aae9577885d4385b704577105018b212647b743c.json
?:pmc_json_files	document_parses/pmc_json/PMC7807228.xml.json
?:pmcid	<https://research.tib.eu/covid-19/entity/PMC7807228>
?:pmid	<https://research.tib.eu/covid-19/entity/33446136.0>
?:pmid	33446136.0
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
?:sha_id	<https://research.tib.eu/covid-19/entity/aae9577885d4385b704577105018b212647b743c>
?:source	Medline; PMC
?:title	Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:year	2021-01-14

Property

Value

?:abstract

BACKGROUND: Hydroxychloroquine has not been associated with improved survival among hospitalized COVID-19 patients in the majority of observational studies and similarly was not identified as an effective prophylaxis following exposure in a prospective randomized trial. We aimed to explore the role of hydroxychloroquine therapy in mildly symptomatic patients diagnosed in the outpatient setting. METHODS: We examined the association between outpatient hydroxychloroquine exposure and the subsequent progression of disease among mildly symptomatic non-hospitalized patients with documented SARS-CoV-2 infection. The primary outcome assessed was requirement of hospitalization. Data was obtained from a retrospective review of electronic health records within a New Jersey USA multi-hospital network. We compared outcomes in patients who received hydroxychloroquine with those who did not applying a multivariable logistic model with propensity matching. RESULTS: Among 1274 outpatients with documented SARS-CoV-2 infection 7.6% were prescribed hydroxychloroquine. In a 1067 patient propensity matched cohort, 21.6% with outpatient exposure to hydroxychloroquine were hospitalized, and 31.4% without exposure were hospitalized. In the primary multivariable logistic regression analysis with propensity matching there was an association between exposure to hydroxychloroquine and a decreased rate of hospitalization from COVID-19 (OR 0.53; 95% CI, 0.29, 0.95). Sensitivity analyses revealed similar associations. QTc prolongation events occurred in 2% of patients prescribed hydroxychloroquine with no reported arrhythmia events among those with data available. CONCLUSIONS: In this retrospective observational study of SARS-CoV-2 infected non-hospitalized patients hydroxychloroquine exposure was associated with a decreased rate of subsequent hospitalization. Additional exploration of hydroxychloroquine in this mildly symptomatic outpatient population is warranted. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-021-05773-w.

?:creator